169 related articles for article (PubMed ID: 31678079)
1. Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center.
Kodad SG; Sutherland H; Limvorapitak W; Abou Mourad Y; Barnett MJ; Forrest D; Gerrie A; Hogge DE; Nantel SH; Narayanan S; Nevill T; Power M; Sanford D; Toze C; White J; Broady R; Song K
Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):784-790. PubMed ID: 31678079
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation.
Obiozor C; Subramaniam DP; Divine C; Shune L; Singh AK; Lin TL; Abhyankar S; Chen GJ; McGuirk J; Ganguly S
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1641-1645. PubMed ID: 28603071
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
4. Safety and survival outcomes for bloodless transplantation in patients with myeloma.
Joseph NS; Kaufman JL; Boise LH; Valla K; Almaula DK; Obidike CO; Langston AA; Waller EK; Khoury HJ; Flowers CR; Graiser M; Heffner LT; Lonial S; Nooka AK
Cancer; 2019 Jan; 125(2):185-193. PubMed ID: 30480777
[TBL] [Abstract][Full Text] [Related]
5. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
6. Revisiting the Utility of Granulocyte Colony-Stimulating Factor Post-Autologous Hematopoietic Stem Cell Transplantation for Outpatient-Based Transplantations.
Portuguese AJ; Holmberg L; Hill GR; Lee SJ; Green DJ; Mielcarek M; Gooley T; Yeh AC
Transplant Cell Ther; 2023 Nov; 29(11):696.e1-696.e7. PubMed ID: 37634844
[TBL] [Abstract][Full Text] [Related]
7. Risk of febrile neutropenia among patients with multiple myeloma or lymphoma who undergo inpatient versus outpatient autologous stem cell transplantation: a systematic review and meta-analysis.
Owattanapanich W; Suphadirekkul K; Kunacheewa C; Ungprasert P; Prayongratana K
BMC Cancer; 2018 Nov; 18(1):1126. PubMed ID: 30445930
[TBL] [Abstract][Full Text] [Related]
8. Outpatient autologous stem cell transplantation in Royal Hobart Hospital, Tasmania: a single-centre, retrospective review in the Australian setting.
Tan XN; Yew CY; Ragg SJ; Harrup RA; Johnston AM
Intern Med J; 2022 Jul; 52(7):1242-1250. PubMed ID: 33949777
[TBL] [Abstract][Full Text] [Related]
9. Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents.
Vaxman I; Visram A; Kumar S; Dispenzieri A; Buadi F; Dingli D; Lacy M; Muchtar E; Kapoor P; Hogan W; Hayman S; Leung N; Gonsalves W; Kourelis T; Warsame R; Berger T; Gertz MA
Bone Marrow Transplant; 2021 May; 56(5):1144-1150. PubMed ID: 33273658
[TBL] [Abstract][Full Text] [Related]
10. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
12. Safety and cost-effectiveness of outpatient autologous stem cell transplantation in patients with multiple myeloma.
Holbro A; Ahmad I; Cohen S; Roy J; Lachance S; Chagnon M; LeBlanc R; Bernard L; Busque L; Roy DC; Sauvageau G; Kiss TL
Biol Blood Marrow Transplant; 2013 Apr; 19(4):547-51. PubMed ID: 23253556
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness, Safety, and Cost Implications of Outpatient Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma.
Marini J; Maldonado A; Weeda E; Neppalli A; Hashmi H; Edwards K
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):351-357. PubMed ID: 37363969
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
[TBL] [Abstract][Full Text] [Related]
15. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
[TBL] [Abstract][Full Text] [Related]
16. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
17. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
Leger C; Sabloff M; McDiarmid S; Bence-Bruckler I; Atkins H; Bredeson C; Zhang H; Huebsch L
Ann Hematol; 2006 Oct; 85(10):723-9. PubMed ID: 16832675
[TBL] [Abstract][Full Text] [Related]
18. Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma.
Singh Abbi KK; Zheng J; Devlin SM; Giralt S; Landau H
Biol Blood Marrow Transplant; 2015 Mar; 21(3):468-72. PubMed ID: 25529381
[TBL] [Abstract][Full Text] [Related]
19. Autologous stem cell transplantation in elderly patients with multiple myeloma: evaluation of its safety and efficacy.
Stettler J; Novak U; Baerlocher GM; Seipel K; Mansouri Taleghani B; Pabst T
Leuk Lymphoma; 2017 May; 58(5):1076-1083. PubMed ID: 27736269
[TBL] [Abstract][Full Text] [Related]
20. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
